/BMXXY

BMXXY Stock - bioMérieux S.A.

Q: What is the analyst price target for BMXXY?

Analyst price target information is not currently available for BMXXY.

Q: What is BMXXY's market cap?

Market capitalization information is not currently available for BMXXY.

Healthcare|Medical - Specialties|OTC

$12.43+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $13.67

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BMXXY

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.65

52W High$15.61

52W Low$9.51

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$3.98B	$3.67B	$3.59B	$3.38B	$3.12B
Gross Profit	$2.22B	$2.06B	$1.96B	$1.97B	$1.74B
Gross Margin	55.7%	56.0%	54.6%	58.3%	55.7%
Operating Income	$588.80M	$439.00M	$587.20M	$784.30M	$551.20M
Net Income	$432.20M	$357.60M	$452.30M	$601.10M	$404.40M
Net Margin	10.9%	9.7%	12.6%	17.8%	13.0%
EPS	$0.37	$0.30	$0.38	$0.51	$0.34

Company Overview

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Visit Website

Earnings History & Surprises

BMXXY

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$0.16

Q3 2025

EPS Surprise History

Q4 21

No data

Q2 22

No data

Q4 22

No data

Q2 23

No data

Q2 24

No data

Q4 24

No data

Q1 25

No data

Q3 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 5, 2026	—	—	—	—
Q3 2025	Sep 4, 2025	—	$0.16	—	—
Q1 2025	Mar 7, 2025	—	$0.19	—	—
Q4 2024	Oct 30, 2024	—	$0.20	—	—
Q2 2024	May 23, 2024	—	$0.18	—	—
Q2 2023	Jun 30, 2023	—	$0.15	—	—
Q4 2022	Dec 31, 2022	—	$0.20	—	—
Q2 2022	Jun 30, 2022	—	$0.20	—	—
Q4 2021	Dec 31, 2021	—	$0.31	—	—
Q2 2021	Jun 30, 2021	—	$0.28	—	—
Q4 2020	Dec 31, 2020	—	$0.24	—	—
Q2 2020	Jun 30, 2020	—	$0.16	—	—
Q4 2019	Dec 31, 2019	—	$0.13	—	—
Q2 2019	Jun 30, 2019	—	$0.13	—	—
Q4 2018	Dec 31, 2018	—	$0.12	—	—
Q2 2018	Jun 30, 2018	—	$0.13	—	—
Q4 2017	Dec 31, 2017	—	$0.14	—	—
Q2 2017	Jun 30, 2017	—	$0.10	—	—
Q4 2016	Dec 31, 2016	—	$0.08	—	—
Q2 2016	Jun 30, 2016	—	$0.08	—	—